Calgary Biotech Company “CardiAI” Receives Provincial Regulatory Approval for New Laboratory

Calgary-based Canadian healthcare innovator and biotech company, CardiAI Inc. announced today that its new state-of-the-art laboratory has met all the Provincial regulatory requirements to run various diagnostic tests including the COVID-19 CoviLamp-PCR and COVID-19 antibody tests.

CALGARY, Alberta--(BUSINESS WIRE)-- Calgary-based Canadian healthcare innovator and biotech company, CardiAI Inc. announced today that its new state-of-the-art laboratory has met all the Provincial regulatory requirements to run various diagnostic tests including the COVID-19 CoviLamp-PCR and COVID-19 antibody tests. CoviLamp-PCR is a new laboratory-developed test which uses a proprietary diagnostic process to provide highly accurate results in under 30 minutes.

The CoviLamp-PCR test is cost effective, easily deployable and can be run on multiple platforms, providing rapid results in a wide range of healthcare settings including physicians’ offices, urgent care clinics, and hospital emergency departments. Crucially, it can also be used effectively in remote locations without access to specialist equipment using a simple plate heater.

“CoviLamp-PCR is providing the opportunity to dramatically expand COVID-19 testing capacity in Alberta without sacrificing accuracy,” said Dr Anmol Kapoor CEO, CardiAI/Advanced Cardiology Consultants. “Our proprietary Laboratory Developed Test has the ability to dramatically increase testing capacity and help get ahead of the curve with this devastating virus.”

To book a test, members of the public can visit www.cardiai.com. Those with commercial requirements can contact +1 (800) 403-8122.

Contacts

Christian Darbyshire | Christian@tinepublic.com | 416-419-9953

Source: CardiAI Inc.

MORE ON THIS TOPIC